… to daily oral risedronate for prevention and treatment of glucocorticoid-induced osteoporosis.
… Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: …

… Conclusion: Yearly zoledronic acid presents a new option for the treatment of postmenopausal
osteoporosis, with the perspective of improving the long-term persistence of therapy …

… osteoporosis market. Although there are no final results from head-to-head antifracture
osteoporosis … ZOL to date is the HORIZON glucocorticoid-induced osteoporosis trial in which 833 …

… Bone turnover biomarker detection may be useful in monitoring osteoporosis treatment and
assessing fracture risk but not for diagnosis of osteoporosis. Management of osteoporosis …

… Regarding age-related osteoporosis, senescent cells accumulate in bone with aging both
in mice and humans (32). Elimination of senescent cells from p16 Ink4a -INK-ATTAC mice led …

… In HORIZON, 7736 postmenopausal women aged 65 to 89 years were stratified into two
groups based on current use of other osteoporosis medications and were randomized within the …

… , hip and other fractures in women with postmenopausal osteoporosis treated over a period
of 3 years. The HORIZON Recurrent Fracture Trial demonstrated that an annual infusion of …

… This study was a post hoc analysis of the HORIZON Pivotal Fracture Trial evaluating the …
women with osteoporosis receiving either zoledronic acid or placebo from the HORIZON Pivotal …

… -line anti-osteoporosis therapy; the new concept of ‘very high fracture risk’ which should
prompt consideration of use of parenteral anti-osteoporosis therapy; new guidance regarding …

… for the management of primary osteoporosis in women. Expert opinion: The availability of
new therapeutic agents makes clinical decision making in osteoporosis more complex. …